通过小分子向HSP90和HSP70来克服癌症药物耐药性
Ren-Duan Cai1, Ming-Jing Lin1, Qing-Mei Ye2,1
1These authors contributed equally to this work.
Cancer drug resistance (Alhambra, Calif.)
|December 22, 2025
概括
热冲击蛋白 (HSP) 在抗癌药物耐药性方面至关重要. 针对小分子抑制剂的HSP显示出增强癌症治疗的前景,尽管临床应用目前面临挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 热冲击蛋白 (HSP) 极大地影响癌症的进展和耐药性.
- HSP90和HSP70是抗药性癌细胞生存的关键.
- 针对HSP提供了一个潜在的策略,以克服癌症药物耐药性.
研究的目的:
- 审查用于癌症治疗的小分子HSP抑制剂.
- 总结HSP抑制剂开发和临床试验方面的进展.
- 讨论癌症中HSP抑制的机制,组合,挑战和解决方案.
主要方法:
- 对HSP抑制剂的药物化学的综述 (凝丹胺衍生物,基于树脂醇的,纯素支架).
- 最近的进展和临床试验进展的总结.
- 对行动机制和组合策略的分析.
主要成果:
- HSP 抑制剂诱导亡并使抗癌细胞对各种治疗产生敏感性.
- 几种HSP抑制剂正在临床试验中,显示出治疗潜力.
- 挑战包括毒性,有限的结果和缺乏特异性.
结论:
- 小分子HSP抑制剂是克服癌症多药耐药性的有希望的治疗途径.
- 需要进一步的研究和开发来应对当前的挑战,并优化HSP抑制剂的疗效.
- 涉及HSP抑制剂的组合疗法可能会改善治疗结果.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K


